Pharmaceutical composition for soft contact lenses

By mixing low concentrations of alkyldiaminoethylglycine hydrochloride and menthol into a pharmaceutical composition for soft contact lenses, and adding taurine, the adsorption problem of alkyldiaminoethylglycine hydrochloride was solved, resulting in higher stability and safety.

CN118903441APending Publication Date: 2024-11-08SENJU PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411076156.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-11-29
Filing Date
2020-11-26
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In existing pharmaceutical compositions for soft contact lenses, alkyl diaminoethyl glycine hydrochloride is readily adsorbed onto the eyeglasses, and the addition of menthol further enhances this tendency, leading to discomfort and potential cytotoxicity issues.

Method used

By mixing low concentrations of alkyldiaminoethylglycine hydrochloride and menthol into the pharmaceutical composition and adding taurine, the adsorption of alkyldiaminoethylglycine hydrochloride onto soft contact lenses is inhibited.

Benefits of technology

It effectively inhibited the adsorption of alkyl diaminoethyl glycine hydrochloride to soft contact lenses, reduced discomfort and cytotoxicity, and improved the stability and safety of the pharmaceutical composition.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004982318780000201
    Figure BDA0004982318780000201
  • Figure BDA0004982318780000211
    Figure BDA0004982318780000211
  • Figure BDA0004982318780000221
    Figure BDA0004982318780000221
Patent Text Reader

Abstract

The purpose of the present invention is to provide a pharmaceutical composition for soft contact lenses, which suppresses adsorption of alkyl diaminoethyl glycine to soft contact lenses. The pharmaceutical composition for soft contact lenses according to the present invention contains 0.001 w / v% or more and 0.0045 w / v% or less of alkyl diaminoethyl glycine hydrochloride, menthol, and taurine.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of a patent application with an application date of November 26, 2020, application number 202080082023.5, and invention name “Pharmaceutical composition for soft contact lenses”. Technical Field

[0002] The present invention relates to a pharmaceutical composition for soft contact lenses which inhibits adsorption of alkyldiaminoethylglycine to soft contact lenses. Background Art

[0003] In order to reduce the discomfort when wearing soft contact lenses or hard contact lenses, various pharmaceutical compositions for soft contact lenses with tear-like components have been studied. Tears are a mixture of more than four substances secreted from the accessory lacrimal glands in the lacrimal gland secretion from the main lacrimal gland, including Na, K, Ca, Cl, etc. as inorganic components, and glucose, ascorbic acid, citric acid, urea, ammonia, amino acids, proteins, etc. as organic components. Although there are individual differences, the concentration of glucose contained in tears is about 0.001 to 0.01 w / v%. However, glucose is sometimes mixed as a nutrient in aqueous liquid preparations for ophthalmology at a higher concentration than tears. For example, the glucose concentration in the aqueous liquid preparations for ophthalmology disclosed in patent documents 1 to 4 is about 0.1 w / v%. On the other hand, among bacteria, there are bacteria that metabolize glucose to produce pyruvic acid to obtain energy, and glucose sometimes promotes the proliferation of such bacteria. Therefore, in particular, ophthalmic aqueous liquid preparations with reduced content of storage agents and preservatives are generally formulated with glucose at a lower concentration than that of tears.

[0004] Even if the concentration of glucose is reduced, a preservative is mixed in the pharmaceutical composition for the purpose of preservation. However, since eye drops are directly applied to the eyes, preservatives sometimes show side effects. For example, non-patent documents 1 to 5 state that preservatives such as benzalkonium chloride damage cells and cause irritation to the skin, and that povidone iodine has the lowest toxicity and alkyldiaminoethylglycine has a moderate toxicity. Patent documents 1 to 4 also disclose ophthalmic compositions containing alkyldiaminoethylglycine hydrochloride.

[0005] In addition, some eye drops contain monoterpenes such as l-menthol in order to impart a cooling sensation (Patent Documents 1, 3, and 5 to 9).

[0006] Prior art literature

[0007] Patent Literature

[0008] Patent Document 1: Japanese Patent Application Publication No. 2001-302518

[0009] Patent Document 2: Japanese Patent Application Publication No. 2001-302545

[0010] Patent Document 3: Japanese Patent Application Publication No. 2009-46480

[0011] Patent Document 4: Japanese Patent Application Publication No. 2005-336153

[0012] Patent Document 5: Japanese Patent Application Publication No. 2011-93888

[0013] Patent Document 6: Japanese Patent Application Publication No. 2011-213729

[0014] Patent Document 7: Japanese Patent Application Publication No. 2007-99643

[0015] Patent Document 8: Japanese Patent Application Publication No. 2014-15417

[0016] Patent Document 9: Japanese Patent Application Publication No. 2015-78248

[0017] Non-patent literature

[0018] Non-patent document 1: Nobuo Takahashi et al., Japanese Ophthalmology, 58: 10, pp. 945-950 (1987)

[0019] Non-patent document 2: Akiyoshi Tsuji et al., Japanese Environmental Sensing, Vol. 11, No. 3, pp. 207-220 (1996)

[0020] Non-patent document 3: Toshiko, Vol.12, No.4, pp.67~73 (2003)

[0021] Non-patent document 4: Nakajima Keiji et al., Nikki Pharmacopoeia, Vol. 40, No. 12, pp. 1559-1562 (2004)

[0022] Non-patent document 5: Shiraishi Masaru, Journal of the Japanese Society of Internal Medicine, Vol.99, No.8, pp.166-172 (2010) Summary of the invention

[0023] Problems to be solved by the invention

[0024] An object of the present invention is to provide a pharmaceutical composition for soft contact lenses which inhibits adsorption of alkyldiaminoethylglycine to soft contact lenses.

[0025] Methods for solving problems

[0026] The present inventors have conducted intensive studies to solve the above problems. As a result, they have found that when a low concentration of alkyldiaminoethylglycine hydrochloride is added to a pharmaceutical composition for soft contact lenses, alkyldiaminoethylglycine has a tendency to be adsorbed to soft contact lenses, and that the tendency is further enhanced by adding menthol, but such adsorption is suppressed by adding taurine, thereby completing the present invention.

[0027] One aspect of the present invention is shown below.

[0028] [1] A pharmaceutical composition for soft contact lenses, comprising 0.001 w / v% to 0.0045 w / v% of alkyldiaminoethylglycine hydrochloride, menthol, and taurine.

[0029] [2] The pharmaceutical composition for soft contact lenses according to [1] above, comprising 0.002 w / v% to 0.004 w / v% of alkyldiaminoethylglycine hydrochloride.

[0030] [3] The pharmaceutical composition for soft contact lenses according to [1] or [2] above, wherein the menthol is l-menthol.

[0031] [4] The pharmaceutical composition for soft contact lens according to any one of [1] to [3] above, comprising 0.0005 w / v% to 0.1 w / v% of menthol.

[0032] [5] The pharmaceutical composition for soft contact lens according to any one of [1] to [3] above, comprising 0.001 w / v% to 0.035 w / v% of menthol.

[0033] [6] The pharmaceutical composition for soft contact lens according to any one of [1] to [3] above, comprising 0.001 w / v% to 0.02 w / v% of menthol.

[0034] [7] The pharmaceutical composition for soft contact lens according to any one of [1] to [6] above, comprising 0.01 w / v% to 1 w / v% of taurine.

[0035] [8] The pharmaceutical composition for soft contact lens according to any one of [1] to [6] above, comprising 0.05 w / v% to 0.5 w / v% of taurine.

[0036] [9] The pharmaceutical composition for soft contact lenses according to any one of [1] to [8] above, comprising:

[0037] 0.002 w / v% or more and 0.004 w / v% or less of alkyldiaminoethylglycine hydrochloride,

[0038] 0.001 w / v% to 0.035 w / v% of menthol, and

[0039] 0.05 w / v% or more and 0.5 w / v% or less of taurine.

[0040]

[10] The pharmaceutical composition for soft contact lens according to any one of [1] to [9] above, further comprising a nonionic surfactant.

[0041]

[11] According to the pharmaceutical composition for soft contact lenses described in

[10] above, the nonionic surfactant is one or more nonionic surfactants selected from polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan mono-long chain fatty acid esters, mono-long chain fatty acids, and polyoxyethylene polyoxypropylene block copolymers.

[0042]

[12] The pharmaceutical composition for soft contact lenses according to

[11] above, wherein the polyoxyethylene hydrogenated castor oil is polyoxyethylene hydrogenated castor oil 60.

[0043]

[13] The pharmaceutical composition for soft contact lens according to any one of

[10] to

[12] above, wherein the concentration of the nonionic surfactant is 0.001 w / v% to 0.5 w / v%.

[0044]

[14] The pharmaceutical composition for soft contact lens according to any one of

[10] to

[13] above, wherein the concentration of the nonionic surfactant is 0.001 w / v % or more and 0.1 w / v % or less.

[0045]

[15] The pharmaceutical composition for soft contact lens according to any one of

[10] to

[13] above, wherein the concentration of the nonionic surfactant is 0.005 w / v% to 0.05 w / v%.

[0046]

[16] The pharmaceutical composition for soft contact lens according to any one of [1] to

[15] above, further comprising glucose.

[0047]

[17] The pharmaceutical composition for soft contact lens according to

[16] above, comprising 0.001 w / v% to 0.01 w / v% glucose.

[0048]

[18] The pharmaceutical composition for soft contact lens according to

[16] above, comprising 0.002 w / v% to 0.008 w / v% glucose.

[0049]

[19] The pharmaceutical composition for soft contact lens according to any one of [1] to

[18] above, further comprising an inorganic salt.

[0050]

[20] The pharmaceutical composition for soft contact lenses according to the above

[19] , wherein the inorganic salt is sodium chloride and / or potassium chloride.

[0051]

[21] The pharmaceutical composition for soft contact lens according to

[19] or

[20] above, comprising 0.05 w / v% to 5 w / v% of an inorganic salt.

[0052]

[22] The pharmaceutical composition for soft contact lens according to

[19] or

[20] above, comprising 0.1 w / v% to 2 w / v% of an inorganic salt.

[0053]

[23] The pharmaceutical composition for soft contact lens according to any one of [1] to

[22] above, further comprising a thickener.

[0054]

[24] The pharmaceutical composition for soft contact lenses according to

[23] above, wherein the thickener is hydroxypropylmethylcellulose.

[0055]

[25] The pharmaceutical composition for soft contact lens according to

[23] or

[24] above, comprising 0.01 w / v% to 1 w / v% of a thickener.

[0056]

[26] The pharmaceutical composition for soft contact lens according to

[23] or

[24] above, comprising 0.05 w / v% to 0.5 w / v% of a thickener.

[0057]

[27] The pharmaceutical composition for soft contact lens according to any one of [1] to

[26] above, further comprising a buffer.

[0058]

[28] The pharmaceutical composition for soft contact lenses according to

[27] above, wherein the buffer is one or more buffers selected from the group consisting of boric acid buffer, phosphate buffer, carbonate buffer, citric acid buffer, acetic acid buffer, HEPES buffer, and MOPS buffer.

[0059]

[29] The pharmaceutical composition for soft contact lens according to

[27] or

[28] above, wherein the buffer is boric acid and / or borax.

[0060]

[30] The pharmaceutical composition for soft contact lens according to any one of

[27] to

[29] above, comprising 0.05 w / v% to 5 w / v% of a buffer.

[0061]

[31] The pharmaceutical composition for soft contact lens according to any one of

[27] to

[29] above, comprising 0.1 w / v% to 1 w / v% of a buffer.

[0062]

[32] The pharmaceutical composition for soft contact lens according to any one of [1] to

[31] above, further comprising a pH adjuster.

[0063]

[33] The pharmaceutical composition for soft contact lens according to any one of [1] to

[32] above, wherein the pH thereof is 5.5 or higher and 8.0 or lower.

[0064]

[34] The pharmaceutical composition for soft contact lens according to any one of [1] to

[32] above, wherein the pH thereof is 6.5 or higher and 7.5 or lower.

[0065]

[35] The pharmaceutical composition for soft contact lenses according to any one of [1] to

[34] above, comprising:

[0066] 0.002 w / v% or more and 0.004 w / v% or less of alkyldiaminoethylglycine hydrochloride,

[0067] 0.001 w / v% to 0.035 w / v% of menthol,

[0068] 0.05 w / v% or more and 0.5 w / v% or less of taurine,

[0069] 0.005 w / v% or more and 0.05 w / v% or less of a nonionic surfactant,

[0070] 0.002 w / v% or more and 0.008 w / v% or less of glucose,

[0071] 0.1w / v% or more and 2w / v% or less of inorganic salts,

[0072] 0.05 w / v% or more and 0.5 w / v% or less of a thickener, and

[0073] 0.1 w / v% or more and 2 w / v% or less of a buffer.

[0074]

[36] The pharmaceutical composition for soft contact lenses according to any one of [1] to

[35] above, comprising:

[0075] 0.002 w / v% or more and 0.004 w / v% or less of alkyldiaminoethylglycine hydrochloride,

[0076] 0.001 w / v% to 0.035 w / v% of menthol,

[0077] 0.05 w / v% or more and 0.5 w / v% or less of taurine,

[0078] 0.005 w / v% or more and 0.05 w / v% or less of a nonionic surfactant,

[0079] 0.002 w / v% or more and 0.008 w / v% or less of glucose,

[0080] 0.1w / v% or more and 2w / v% or less of inorganic salts,

[0081] 0.05 w / v% or more and 0.5 w / v% or less of a thickener, and

[0082] 0.1 w / v% or more and 2 w / v% or less of a buffer,

[0083] The pH of the pharmaceutical composition for soft contact lenses is 5.5 or more and 7.5 or less.

[0084]

[37] The pharmaceutical composition for soft contact lens according to any one of [1] to

[36] above, further comprising an amino acid.

[0085]

[38] The pharmaceutical composition for soft contact lenses according to

[37] above, wherein the amino acid is one or more amino acids selected from glutamic acid, aspartic acid, glycine, alanine, arginine, lysine, and salts thereof.

[0086]

[39] The pharmaceutical composition for soft contact lens according to

[37] or

[38] above, comprising 0.01 w / v% to 1 w / v% of an amino acid.

[0087]

[40] The pharmaceutical composition for soft contact lens according to

[37] or

[38] above, comprising 0.05 w / v% to 0.5 w / v% of an amino acid.

[0088]

[41] The pharmaceutical composition for soft contact lens according to any one of [1] to

[40] above, further comprising a chelating agent.

[0089]

[42] The pharmaceutical composition for soft contact lenses according to

[41] above, wherein the chelating agent is ethylenediaminetetraacetic acid or a salt thereof.

[0090]

[43] The pharmaceutical composition for soft contact lens according to

[41] or

[42] above, which contains 0.001 w / v% to 0.1 w / v% of a chelating agent.

[0091]

[44] The pharmaceutical composition for soft contact lens according to

[41] or

[42] above, comprising 0.005 w / v% to 0.05 w / v% of a chelating agent.

[0092]

[45] The pharmaceutical composition for soft contact lenses according to any one of [1] to

[44] above, comprising:

[0093] 0.002 w / v% or more and 0.004 w / v% or less of alkyldiaminoethylglycine hydrochloride,

[0094] 0.001 w / v% to 0.035 w / v% of menthol,

[0095] 0.05 w / v% or more and 0.5 w / v% or less of taurine,

[0096] 0.005 w / v% or more and 0.05 w / v% or less of a nonionic surfactant,

[0097] 0.002 w / v% or more and 0.008 w / v% or less of glucose,

[0098] 0.1w / v% or more and 2w / v% or less of inorganic salts,

[0099] 0.05 w / v% or more and 0.5 w / v% or less of a thickener,

[0100] 0.1 w / v% or more and 2 w / v% or less of a buffer, and

[0101] 0.005 w / v% or more and 0.1 w / v% or less of the chelating agent.

[0102]

[46] The pharmaceutical composition for soft contact lenses according to any one of [1] to

[45] above, comprising:

[0103] 0.002 w / v% or more and 0.004 w / v% or less of alkyldiaminoethylglycine hydrochloride,

[0104] 0.001 w / v% to 0.035 w / v% of menthol,

[0105] 0.05 w / v% or more and 0.5 w / v% or less of taurine,

[0106] 0.005 w / v% or more and 0.05 w / v% or less of a nonionic surfactant,

[0107] 0.002 w / v% or more and 0.008 w / v% or less of glucose,

[0108] 0.1w / v% or more and 2w / v% or less of inorganic salts,

[0109] 0.05 w / v% or more and 0.5 w / v% or less of a thickener,

[0110] 0.1 w / v% or more and 2 w / v% or less of a buffer, and

[0111] 0.005 w / v% or more and 0.1 w / v% or less of a chelating agent,

[0112] The pH of the pharmaceutical composition for soft contact lenses is 6.5 or more and 7.5 or less.

[0113]

[47] The pharmaceutical composition for soft contact lens according to any one of [1] to

[46] above, which is used in ophthalmology.

[0114]

[48] ​​The pharmaceutical composition for soft contact lenses according to any one of [1] to

[47] above, which is an aqueous liquid preparation.

[0115]

[49] The pharmaceutical composition for soft contact lenses according to any one of [1] to

[48] above, which is an eye drop.

[0116]

[50] Use of taurine for inhibiting adsorption of alkyldiaminoethylglycine to a soft contact lens in a pharmaceutical composition comprising 0.001 w / v% to 0.0045 w / v% of alkyldiaminoethylglycine hydrochloride and menthol.

[0117]

[51] Use of taurine for producing a pharmaceutical composition for inhibiting adsorption of alkyldiaminoethylglycine to a soft contact lens in a pharmaceutical composition comprising 0.001 w / v% to 0.0045 w / v% of alkyldiaminoethylglycine hydrochloride and menthol.

[0118]

[52] A method for inhibiting the adsorption of alkyldiaminoethylglycine to soft contact lenses,

[0119] The content of alkyldiaminoethylglycine hydrochloride in the pharmaceutical composition for soft contact lenses is 0.001 w / v% or more and 0.0045 w / v% or less,

[0120] Menthol and taurine are mixed in the pharmaceutical composition for soft contact lenses.

[0121]

[53] The method according to

[52] above, wherein the content of alkyldiaminoethylglycine hydrochloride in the pharmaceutical composition for soft contact lenses is 0.002 w / v% or more and 0.004 w / v% or less.

[0122] The provisions of [1] to

[49] above can be applied to the above-mentioned “use of taurine for producing a pharmaceutical composition for inhibiting adsorption of alkyldiaminoethylglycine to soft contact lenses in a pharmaceutical composition” and “method for inhibiting adsorption of alkyldiaminoethylglycine to soft contact lenses”.

[0123] Effects of the Invention

[0124] The pharmaceutical composition for soft contact lenses according to the present invention contains alkyldiaminoethylglycine hydrochloride, but adsorption of alkyldiaminoethylglycine to soft contact lenses is suppressed. DETAILED DESCRIPTION

[0125] As described above, various pharmaceutical compositions have been developed, and preservatives are mixed in eye drops for the purpose of storage stability. Among the preservatives used in pharmaceutical compositions, alkyldiaminoethylglycine hydrochloride has a lower cytotoxicity than benzalkonium chloride and the like.

[0126] However, the present inventors have found that when alkyldiaminoethylglycine hydrochloride is mixed at a relatively low concentration in a pharmaceutical composition for soft contact lenses, alkyldiaminoethylglycine tends to be adsorbed to soft contact lenses, and this tendency is further enhanced by the addition of menthol. Therefore, the present inventors have studied components that inhibit such adsorption, and found that taurine is effective.

[0127] The pharmaceutical composition for soft contact lenses according to the present invention contains 0.001 w / v% or more and 0.0045 w / v% or less of alkyldiaminoethylglycine hydrochloride, menthol, and taurine.

[0128] Hereinafter, alkyldiaminoethylglycine may be abbreviated as "ADG", and soft contact lens may be abbreviated as "SCL".

[0129] "Alkyldiaminoethylglycine hydrochloride" is a compound having the following chemical structure, and has been used mainly as a preservative component in the past.

[0130] R-NH-(CH2)2-NH-(CH2)2-NH-CH2-CO2H·HCl

[0131] [wherein, R represents C8H 17 ~C 16 H 33 The alkyl groups are mainly C 12 H 25 and C 14 H 29 . ]

[0132] In order to provide a pharmaceutical composition for soft contact lenses with low cytotoxicity, the present inventors set the compounding amount of alkyldiaminoethylglycine hydrochloride in the pharmaceutical composition for soft contact lenses to a relatively low level of 0.001 w / v% or more and 0.0045 w / v% or less. If the concentration is 0.001 w / v% or more, the antiseptic effect is more reliably exerted. On the other hand, if the concentration is 0.0045 w / v% or less, the cytotoxicity, etc. are more reliably suppressed. In addition, the present inventors have found through experiments that when the concentration is 0.0045 w / v% or less, the adsorption inhibition effect of alkyldiaminoethylglycine on soft contact lenses is improved. As the concentration, it is more preferably 0.002 w / v% or more and 0.004 w / v% or less.

[0133] In the pharmaceutical composition for soft contact lenses according to the present invention, menthol is blended from the viewpoint of a cooling sensation. Although the adsorption of ADG to soft contact lenses is promoted by the blending of menthol, such adsorption is suppressed by the blending of taurine in the present invention. As menthol, both l-menthol and dl-menthol can be used, but l-menthol is preferred.

[0134] The concentration of menthol in the pharmaceutical composition for soft contact lenses can be adjusted appropriately, for example, 0.0005 w / v% or more and 0.1 w / v% or less. If the concentration is within this range, a moderate cooling sensation can be obtained more reliably. The concentration is preferably 0.001 w / v% or more, more preferably 0.0015 w / v% or more, and further preferably 0.002 w / v% or more, and preferably 0.035 w / v% or less, more preferably 0.02 w / v% or less, and further preferably 0.01 w / v% or less or 0.009 w / v% or less.

[0135] "Taurine" is another name for 2-aminoethanesulfonic acid [H2N-(CH2)2-SO3H], which is one of the neurotransmitters and has a homeostatic effect such as lowering elevated blood pressure. It is expected to activate eye tissues as a nutrient, and to promote recovery from eye fatigue and eye diseases. The present inventors have found through experiments that low concentrations of alkyldiaminoethylglycine in a pharmaceutical composition tend to be adsorbed to soft contact lenses, and such a tendency is further promoted by the addition of menthol, but such adsorption of alkyldiaminoethylglycine is suppressed by the addition of taurine.

[0136] The concentration of taurine in the pharmaceutical composition for soft contact lenses can be appropriately adjusted, for example, 0.01 w / v% or more and 1 w / v% or less. The concentration is preferably 0.05 w / v% or more, more preferably 0.08 w / v% or more, and preferably 0.5 w / v% or less, more preferably 0.2 w / v% or less.

[0137] "Nonionic surfactants" are surfactants that do not dissociate into ions even when dissolved in water. Generally, polyoxyethylene chains and hydroxyl groups act as hydrophilic groups, and long-chain alkyl groups become hydrophobic groups. Nonionic surfactants contribute to the stability of eye drops. Examples of nonionic surfactants include one or more nonionic surfactants selected from polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan mono-long chain fatty acid esters, mono-long chain fatty acid polyethylene glycol esters, and polyoxyethylene polyoxypropylene block copolymers.

[0138] The so-called polyoxyethylene hydrogenated castor oil is a compound obtained by etherifying hydrogenated castor oil with a polyoxyethylene chain. The number of moles of ethylene oxide added to the polyoxyethylene chain in the polyoxyethylene hydrogenated castor oil can be, for example, 5 or more and 100 or less. As this number, it is preferably 10 or more or 20 or more, more preferably 30 or more, and further preferably 40 or more. In addition, it is preferably 90 or less, more preferably 80 or less, and further preferably 70 or less. As the polyoxyethylene hydrogenated castor oil, polyoxyethylene hydrogenated castor oil 5, polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 60, etc. can be used, and polyoxyethylene hydrogenated castor oil 60 can be used appropriately. In addition, the number after the polyoxyethylene hydrogenated castor oil represents the number of moles of ethylene oxide added.

[0139] Polyoxyethylene sorbitan mono-long chain fatty acid ester is also called polysorbate. It is a polyoxyethylene ether of sorbitan fatty acid ester obtained by heating sorbitol and long-chain fatty acid under an alkali catalyst to generate sorbitan long-chain fatty acid ester, and condensing ethylene oxide with the sorbitan long-chain fatty acid ester. Usually, a total of 18 or more molecules and 22 or less molecules of ethylene oxide are bound to each molecule. The number of carbon atoms of long-chain fatty acids is generally 10 or more and 20 or less. As long-chain fatty acids, for example, lauric acid, palmitic acid, stearic acid, oleic acid, etc. can be cited. As polyoxyethylene sorbitan mono-long chain fatty acid ester, for example, polysorbate 20, polysorbate 60, polysorbate 65, polysorbate 80 can be used, preferably polysorbate 80.

[0140] The mono-long-chain fatty acid polyethylene glycol ester is an ester of a long-chain fatty acid and polyethylene glycol, and examples of the long-chain fatty acid include stearic acid, and the degree of polymerization of the polyethylene glycol is about 10 to 60. The mono-long-chain fatty acid polyethylene glycol ester is preferably polyoxyl 40 stearate.

[0141] The polyoxyethylene polyoxypropylene block copolymer is a copolymer of propylene oxide and ethylene oxide. Examples of the polyoxyethylene polyoxypropylene block copolymer include polyoxyethylene (160) polyoxypropylene (30) diol (Poloxamer 188), polyoxyethylene (196) polyoxypropylene (67) diol (Poloxamer 407), and poloxamer 235.

[0142] The concentration of the nonionic surfactant in the pharmaceutical composition can be adjusted appropriately, for example, 0.001 w / v% or more and 0.5 w / v% or less. If the concentration is within this range, the stabilizing effect of the pharmaceutical composition can be more effectively exerted. As the concentration, it is preferably 0.005 w / v% or more, more preferably 0.008 w / v% or more, and in addition, it is preferably 0.1 w / v% or less, more preferably 0.05 w / v% or less, and further preferably 0.02 w / v% or less.

[0143] Glucose has the formula C6H 12 One of the aldohexoses represented by O6, also called glucose, exists in nature as D-glucose, and in animals with a respiratory system, it conjugates with the electron transport system to generate a large amount of ATP, and exists in tears at a concentration of more than 1 w / v% and less than 5 w / v%.

[0144] In the pharmaceutical composition for soft contact lenses according to the present invention, it is preferred to mix glucose in an amount of 0.001 w / v% or more and 0.01 w / v% or less. If the ratio is 0.001 w / v% or more, it is considered that the same effect as glucose in tears is exerted, and if the ratio is 0.01 w / v% or less, the stability of the composition can be more reliably ensured. As the ratio, it is more preferably 0.002 w / v% or more, and further preferably 0.004 w / v% or more, and further preferably 0.008 w / v% or less, and further preferably 0.006 w / v% or less.

[0145] The so-called "inorganic salt" refers to an inorganic compound obtained by replacing the hydrogen atoms of an inorganic acid with a metal, and is mainly mixed as an isotonic agent. As an inorganic salt, it is preferably a substance that is soluble in water as a solvent for eye drops. The so-called "soluble in water" means that after the test object is made into a fine powder that can pass through a No. 100 (mesh size: 150 μm) sieve, 1 g is added to water, and when it is vigorously shaken for 30 seconds every 5 minutes at 20°C, the amount of water required to dissolve within 30 minutes is less than 10 mL.

[0146] Examples of the inorganic salt include alkali metal chlorides such as sodium chloride and potassium chloride; Group IIA metal chlorides such as calcium chloride and magnesium chloride; alkali metal carbonates such as sodium carbonate; alkali metal hydrogen carbonates such as sodium hydrogen carbonate; Group IIA metal sulfates such as magnesium sulfate; alkali metal sulfites such as sodium sulfite; alkali metal hydrogen sulfites such as sodium hydrogen sulfite; alkali metal thiosulfates such as sodium thiosulfate; alkali metal hydrogen phosphates such as disodium hydrogen phosphate; alkali metal dihydrogen phosphates such as sodium dihydrogen phosphate and potassium dihydrogen phosphate, and the like. Sodium chloride and / or potassium chloride are preferably used. As the Group IIA metal, an alkaline earth metal such as calcium is preferred.

[0147] The concentration of the inorganic salt in the eye drops can be adjusted appropriately, for example, 0.05 w / v% or more and 5 w / v% or less. If the concentration is within this range, the isotonic effect brought about by the inorganic salt is more surely exerted. As the concentration, it is preferably 0.1 w / v% or more, more preferably 0.5 w / v% or more, and preferably 2 w / v% or less, more preferably 1 w / v% or less. Only one metal chloride may be used, or two or more metal chlorides may be used in combination. When two or more metal chlorides are used, the above concentration is the total concentration.

[0148] The so-called "thickener" is a component that increases the viscosity of the pharmaceutical composition for soft contact lenses and contributes to suppressing rapid evaporation of the pharmaceutical composition for soft contact lenses, improving liquid shear properties, suppressing variation in the amount of drop, improving the feeling of use, etc. In the pharmaceutical composition, glucose is also compounded as an isotonic agent and a thickener, but in the present invention, for convenience, glucose is excluded from the category of thickeners.

[0149] The viscosity of the pharmaceutical composition for soft contact lenses according to the present invention may be appropriately adjusted, and may be, for example, 1.0 mPa·s to 200 mPa·s, preferably 50 mPa·s or less, and more preferably 3.0 mPa·s or less.

[0150] Examples of the thickener include hydroxypropylmethylcellulose, carboxyvinyl polymer, hydroxyethylcellulose, methylcellulose, alginic acid, polyvinyl alcohol, and polyvinyl pyrrolidone, and hydroxypropylmethylcellulose is preferred.

[0151] The concentration of the thickener in the pharmaceutical composition for soft contact lenses can be adjusted appropriately, for example, 0.01 w / v% or more and 1 w / v% or less. If the concentration is within this range, the above-mentioned effect brought about by the thickener is more surely exerted. As the concentration, it is preferably 0.05 w / v% or more, more preferably 0.08 w / v% or more, and preferably 0.5 w / v% or less, more preferably 0.2 w / v% or less.

[0152] The so-called "buffer" refers to a compound mainly used to moderate the change of pH caused by external substances, and for example, one or more buffers selected from boric acid buffer, phosphate buffer, carbonate buffer, citric acid buffer, acetic acid buffer, HEPES buffer, and MOPS buffer can be cited. As the buffer, preferably boric acid buffer or phosphate buffer, more preferably boric acid buffer, and further preferably boric acid and / or borax. Boric acid and borax can also be used as preservatives and also show disinfection effect on conjunctival sac.

[0153] The concentration of the buffer in the pharmaceutical composition for soft contact lenses can be appropriately adjusted, for example, 0.05 w / v% or more and 5 w / v% or less. If the concentration is within this range, the buffering effect brought about by the buffer is more reliably exerted. As the concentration, it is preferably 0.1 w / v% or more, more preferably 0.5 w / v% or more, and preferably 2 w / v% or less, more preferably 1 w / v% or less.

[0154] The so-called "amino acid" is a compound having a carboxyl group and an amino group in one molecule, and mainly refers to 20 kinds of so-called protein-forming amino acids. Amino acids are mainly nutrients for the eyes and help to reduce eye fatigue. Examples of amino acids include, for example, one or more amino acids selected from glutamic acid, aspartic acid, glycine, alanine, arginine, lysine, and salts thereof. Examples of amino acid salts include alkali metal salts such as sodium salts and potassium salts.

[0155] The concentration of the amino acid in the pharmaceutical composition for soft contact lenses can be appropriately adjusted, for example, 0.01 w / v% or more and 1 w / v% or less. If the concentration is within this range, the effect of each amino acid is more reliably exerted. As the concentration, it is preferably 0.05 w / v% or more, more preferably 0.08 w / v% or more, and preferably 0.5 w / v% or less, more preferably 0.2 w / v% or less.

[0156] The pH of the pharmaceutical composition for soft contact lenses of the present invention is adjusted to a range that can be applied to a living body, particularly an eye. The pH may be, for example, 5.0 or more and 8.5 or less, preferably 5.5 or more, more preferably 6.0 or more, and even more preferably 6.5 or more, and preferably 8.0 or less, and more preferably 7.5 or less. The pH of the pharmaceutical composition for soft contact lenses may be adjusted by the above-mentioned buffer or by a pH adjusting agent.

[0157] There are no particular restrictions on the pH adjuster as long as it can be applied to a living body, especially the eye, and examples thereof include inorganic acids such as hydrochloric acid and boric acid; organic acids such as acetic acid, glutamic acid, and aspartic acid; inorganic bases such as sodium hydroxide, sodium carbonate, and sodium bicarbonate; and organic bases such as triethanolamine and monoethanolamine. The type and amount of the pH adjuster may be determined according to the pH to be adjusted in the pharmaceutical composition for soft contact lenses.

[0158] "Chelating agents" improve the stability of eye drops by blocking metal ions such as calcium ions and inhibiting the formation of insoluble metal salts. As chelating agents, there are no particular restrictions as long as they can be applied to organisms, especially eyes, and have such effects. For example, ethylenediaminetetraacetic acid (EDTA), ascorbic acid, citric acid, and salts thereof can be cited. As salts of EDTA, for example, tetrasodium EDTA and disodium EDTA can be cited.

[0159] The concentration of the chelating agent in the pharmaceutical composition for soft contact lenses can be adjusted appropriately, for example, from 0.001 w / v% to 0.2 w / v%. If the concentration is within this range, the stabilization effect brought about by the chelating agent can be more reliably obtained. The concentration is preferably from 0.002 w / v% to 0.005 w / v%, more preferably from 0.1 w / v% to 0.05 w / v%, and even more preferably from 0.02 w / v% to 0.

[0160] In the pharmaceutical composition for soft contact lenses to which the present invention relates, there is no particular limitation within the scope of not damaging the effect of the present invention, but a storage agent or preservative other than alkyl diaminoethyl glycine hydrochloride may be added. As storage agents or preservatives, for example, benzalkonium chloride, benzalkonium bromide, benzethonium chloride, chlorhexidine hydrochloride, chlorhexidine gluconate, chlorhexidine acetate, chlorobutanol, benzyl alcohol, phenethyl alcohol, sorbic acid or its salt, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, dehydroacetic acid or its salt, zinc chloride, polychloride, sodium thiomercurate, butylated hydroxytoluene, sodium chlorite, boric acid, borax, etc. may be enumerated. These storage agents or preservatives may be used alone or in combination of two or more.

[0161] In addition, each of the above components may be used alone or in combination of two or more as appropriate.

[0162] Soft contact lenses are classified into four types by the FDA (Food and Drug Administration). That is, they are classified into Group I: non-ionic soft contact lenses with a water content of less than 50%, Group II: non-ionic soft contact lenses with a water content of 50% or more, Group III: ionic soft contact lenses with a water content of less than 50%, and Group IV: ionic soft contact lenses with a water content of 50% or more. Soft contact lenses with a molar percentage of anionic monomers among the constituent monomers of the raw material polymer of 1% or more are ionic, and soft contact lenses with a molar percentage of less than 1% are non-ionic. The soft contact lenses in the present disclosure may be any of the above-mentioned soft contact lenses, regardless of the difference between ionic or non-ionic, hydrated or non-hydrated.

[0163] In addition, in the present disclosure, “soft contact lenses” include, for example, soft contact lenses with 2-hydroxyethyl methacrylate (HEMA), EGDMA, SiMAA2, mPDMS1000, CE-PDMS, TRIS, EMA, methacryloyloxyethyl phosphorylcholine, TrisVC, MMA, MA, polyethylene glycol monomethacrylate (PEGMA), glyceryl methacrylate (GMA), N,N-dimethylacrylamide (DMA), vinyl alcohol (VA), N-vinyl pyrrolidone (NVP or VP), methacrylic acid (MAA), fluorine-containing methacrylate compounds, silicon-containing methacrylate compounds, silicone hydrogels, cycloalkyl methacrylates, etc. as main components.

[0164] The soft contact lens in the present disclosure may be any of the above materials, but preferably a soft contact lens having 2-hydroxyethyl methacrylate (HEMA) as the main component can be mentioned, and more preferably a soft contact lens having 2-hydroxyethyl methacrylate (HEMA) and EGDMA as the main components, or a soft contact lens having HEMA and methacryloyloxyethyl phosphorylcholine as the main components can be mentioned.

[0165] The type of soft contact lenses is not particularly limited, and disposable soft contact lenses, periodic replacement soft contact lenses, existing soft contact lenses, silicone hydrogel contact lenses, and colored contact lenses can all be used.

[0166] Silicone hydrogel contact lenses are contact lenses made of silicone hydrogel.

[0167] Colored contact lenses are contact lenses that are colored for the purpose of eye decoration, beauty, etc. For example, by wearing colored contact lenses, the color of the iris can be changed. Furthermore, if a contact lens with a larger area than the periphery of the iris is used, the pupil can be made to look larger. Such contact lenses are sometimes called circle lenses.

[0168] As the pigment used for coloring the colored contact lenses, known pigments such as inorganic pigments and organic pigments can be used. Examples of such pigments include azo pigments, phthalocyanine pigments, diketopyrrolopyrrole pigments, anthraquinone pigments, and tribenzophenone pigments. Alkane pigment, violet anthrone pigment, isoindoline pigment, carbazole pigment, quinoline pigment, metal oxide pigment, carbon black etc., according to the color, design etc. of colored contact lens, can be used in combination of one or more than two kinds. In the present disclosure, even if it is called the material of pigment, dye, also can be used by known means. In addition, no matter it is the soft contact lens that is not a colored soft contact lens, or transparent contact lens, sometimes when being immersed in the solution such as cleaning solution, it is colored as light color to the degree that can be easily visually distinguished.

[0169] The pharmaceutical composition for soft contact lenses of the present invention can be prepared by conventional methods. For example, each component can be dissolved in water as a solvent. The water used as the solvent is, for example, distilled water, purified water, sterilized water, etc., clear water in which impurities, bacteria, viruses, fungi, etc. are less than the detection limit or sufficiently small.

[0170] The container of holding the pharmaceutical composition for soft contact lens of the present invention is not particularly limited, as long as it is the container used as eye drop container in the past, can be glass system, in addition can also be plastic system.As the container of holding the pharmaceutical composition for soft contact lens of the present invention, when using plastic system, the constituent material of this plastic container is not particularly limited, for example, can enumerate any one or two or more mixtures in polyethylene naphthalate, polyarylate, polyethylene terephthalate, polybutylene terephthalate, polypropylene, polyethylene, polyimide.Consider from the viewpoint of more surely guaranteeing the stability of the pharmaceutical composition for soft contact lens, as the material of the member of the housing portion that forms the container body, namely holds the pharmaceutical composition for soft contact lens, preferably polyethylene terephthalate, polypropylene or polyethylene, more preferably polyethylene terephthalate.

[0171] The inhibition of adsorption of alkyldiaminoethylglycine to soft contact lenses in the pharmaceutical composition for soft contact lenses of the present invention is evaluated by the following method: the amount of alkyldiaminoethylglycine contained in the pharmaceutical composition for soft contact lenses after immersion of the soft contact lenses is greater than the amount of alkyldiaminoethylglycine after immersion of the soft contact lenses in a liquid of the same composition except that taurine is not contained. The immersion of the soft contact lenses can be performed, for example, by shaking the liquid at 25° C. for 24 hours. The amount of alkyldiaminoethylglycine can be measured by absorbance of light of a wavelength of 545 nm that is unique to alkyldiaminoethylglycine, high performance liquid chromatography, etc.

[0172] The pharmaceutical composition for soft contact lenses according to the present invention assists tear production and is effective in alleviating discomfort, dry eyes, eye fatigue, blurred vision, etc. when wearing soft contact lenses.

[0173] The pharmaceutical composition of the present invention can be used in any form of oral administration or external use according to the purpose. As an oral form, it can be used for internal medicine, etc., and as an external form, it can be provided as a local liquid preparation for various uses such as ophthalmology, dentistry, otolaryngology, dermatology, etc. It is particularly preferably used for ophthalmology.

[0174] The so-called "ophthalmic pharmaceutical composition" refers to a pharmaceutical composition for ophthalmic use. As the pharmaceutical composition, in particular, an aqueous liquid preparation containing water as a solvent can be mentioned. The so-called "aqueous liquid preparation" refers to a liquid pharmaceutical composition containing water as a solvent. The aqueous liquid preparation can be prepared by a conventional method such as dissolving or dispersing each component in water as a solvent, and can be a solution, a suspension, or an emulsion, but is preferably an aqueous liquid preparation as a solution.

[0175] Examples of ophthalmic pharmaceutical compositions include eye drops (including eye drops that can be used while wearing soft contact lenses, also referred to as eye drops or eye drops), eye washes (including eye washes that can be used while wearing soft contact lenses, also referred to as eye wash solutions or eye wash medicines), eye ointments, soft contact lens wearing solutions, and soft contact lens care agents (cleaning solutions, storage solutions, bactericidal solutions, disinfecting solutions {including multi-purpose care solutions}, etc.), preferably eye drops, contact lens wearing solutions, eye washes, or soft contact lens care agents, and particularly preferably soft contact lens care eye drops.

[0176] The pharmaceutical composition of the present invention includes eye drops that can be used while wearing soft contact lenses. That is, the pharmaceutical composition of the present invention can be applied to eyes while wearing soft contact lenses. The types of soft contact lenses are not particularly limited, and disposable soft contact lenses, regularly replaced soft contact lenses, existing soft contact lenses, silicone hydrogel contact lenses, and colored contact lenses can all be used. Silicone hydrogel contact lenses are contact lenses made of silicone hydrogel.

[0177] The usage and dosage of the eye drops of the present invention vary depending on the symptoms, age, etc. of the patient, but usually, the eye drops are instilled once or more and six times or less per day, with 1 drop or more and 3 drops or less each time.

[0178] The container used for the pharmaceutical composition of the present invention is sterilized according to conventional methods. The sterilization method is not particularly limited as long as it is a commonly used method, and examples thereof include dry heat sterilization, electron beam sterilization, gamma ray sterilization, ethylene gas sterilization, etc. In one embodiment, the sterilization treatment is electron beam sterilization.

[0179] The present invention also relates to a method for inhibiting adsorption of alkyldiaminoethylglycine to a soft contact lens, wherein the content of alkyldiaminoethylglycine hydrochloride in a pharmaceutical composition for soft contact lenses is 0.001 w / v% or more and 0.0045 w / v% or less, and menthol and taurine are blended in the pharmaceutical composition for soft contact lenses. In this method, adsorption of alkyldiaminoethylglycine to a soft contact lens is further effectively inhibited when the content of alkyldiaminoethylglycine hydrochloride in the pharmaceutical composition for soft contact lenses is 0.002 w / v% or more and 0.004 w / v% or less.

[0180] In the above-mentioned adsorption inhibition method, the content of alkyldiaminoethylglycine hydrochloride in the pharmaceutical composition for soft contact lens is limited to 0.001 w / v% or more and 0.0045 w / v% or less because the adsorption rate of alkyldiaminoethylglycine to soft contact lens increases in such a low concentration range.

[0181] In the above-mentioned adsorption inhibition method, the types and concentrations of the alkyldiaminoethylglycine hydrochloride, menthol, taurine, and other optional components used may be those related to the above-mentioned pharmaceutical composition for soft contact lenses, either alone or in combination. The same also applies to the pH, container, etc. of the pharmaceutical composition for soft contact lenses.

[0182] This application claims the benefit of priority based on Japanese Patent Application No. 2019-217423 filed on November 29, 2019. The entire contents of the specification of Japanese Patent Application No. 2019-217423 filed on November 29, 2019 are incorporated herein by reference.

[0183] Example

[0184] The present invention is described in more detail below with reference to examples, but the present invention is not limited to the following examples and can be implemented with appropriate modifications within the scope of the aforementioned / later described purpose, all of which are included in the technical scope of the present invention.

[0185] Test Example 1: Adsorption test on soft contact lenses

[0186] The aqueous solution of Example 1 of the composition shown in Table 1 was prepared. Specifically, sodium chloride (manufactured by Nakalai Tesque Co., Ltd.), sodium dihydrogen phosphate dihydrate (manufactured by Nakalai Tesque Co., Ltd.), and disodium hydrogen phosphate 12 hydrate (manufactured by Nakalai Tesque Co., Ltd.) were dissolved in water (80 mL) in such a manner that the concentrations described in Table 1 were finally obtained. The obtained aqueous solution was heated to about 70°C, l-menthol (manufactured by Suzuki Menthol Co., Ltd.) and taurine (manufactured by Kasano Kosan Co., Ltd.) were added and dissolved, and then cooled to room temperature. A 40% alkyldiaminoethylglycine hydrochloride aqueous solution ("Lebon LAG-40" manufactured by Sanyo Chemical Industries, Ltd.) was further added and mixed, and as a pH adjuster, 1 mol / L hydrochloric acid or 1 mol / L sodium hydroxide aqueous solution was used to adjust the pH, and purified water was added to adjust the total volume to 100 mL. Alternatively, the aqueous solution was prepared by geometric multiples thereof.

[0187] In addition, aqueous solutions of Comparative Example 1 and Comparative Example 2 having the compositions shown in Table 1 were prepared according to the above method. The numerical values ​​in Table 1 are expressed in w / v % except for pH and ADG adsorption rate.

[0188] Next, the adsorption of alkyldiaminoethylglycine to soft contact lenses was tested. 3 mL of each test solution was measured into 3 vials, and one soft contact lens ("Wand Acoustic Moisture" manufactured by Dionson Endo) was immersed in each vial, and shaken at 25°C for more than 24 hours to make the SCL immersion solution. Three samples of liquid that was not immersed in soft contact lenses were treated in the same way and made into control test solutions. Next, the content (C) of each alkyldiaminoethylglycine in the SCL immersion solution and the control test solution was determined from the sum of the areas of the peaks derived from alkyldiaminoethylglycine by high performance chromatography (HPLC) under the following conditions.

[0189] Column: 4.6 mm inner diameter x 15 cm length cyanopropyl silylated silica gel ("CN12S05-1546WT" manufactured by Wiemshi Co., Ltd.)

[0190] Detector: UV absorbance photometer

[0191] Measurement wavelength: 210nm

[0192] Mobile phase: water / methanol / phosphoric acid mixture = 750 / 250 / 1

[0193] The average values ​​of the alkyldiaminoethylglycine contents (C) obtained by the measurements were calculated, and the adsorption rate (%) of alkyldiaminoethylglycine to soft contact lenses was calculated according to the following formula. The results are shown in Table 1. In the table, "%" of the amount of each component means w / v%.

[0194] Adsorption rate (%) = 100-{[(C C -C T ) / C C ]×100}

[0195] [Wherein, C T The average value (μg / mL) of the content of alkyldiaminoethylglycine in the SCL immersion solution is shown in C C It shows the average value (μg / mL) of the content of alkyldiaminoethylglycine in the control test solution.]

[0196] Table 1

[0197]

[0198] As shown in the results in Table 1, when menthol was blended in the preparation, the amount of alkyldiaminoethylglycine adsorbed to the soft contact lens increased.

[0199] On the other hand, it was found that when taurine was blended in addition to menthol, the adsorption of alkyldiaminoethylglycine to a soft contact lens was suppressed.

[0200] Test Example 2: Study on the blending amount of alkyl diaminoethyl glycine hydrochloride

[0201] The adsorption rate of alkyldiaminoethylglycine to soft contact lenses was determined under the same conditions as in Test Example 1 using the formulations of Table 2 with different blending amounts of alkyldiaminoethylglycine hydrochloride.

[0202] In addition, the adsorption inhibition rate (%) of alkyldiaminoethylglycine on soft contact lenses was calculated according to the following formula between preparations with the same composition except that taurine was not mixed. The results are shown in Table 2. The values ​​in Table 2 are expressed as w / v% except for pH, ADG adsorption rate and adsorption inhibition rate.

[0203] Adsorption inhibition rate (%) = {[(adsorption rate of the preparation without taurine) - (adsorption rate of the preparation containing taurine)] / (adsorption rate of the preparation without taurine)} × 100

[0204]

[0205] As shown in the results in Table 2, in the preparations in which the concentration of alkyldiaminoethylglycine hydrochloride was in the range of 0.001 to 0.004 w / v%, the amount of adsorption of alkyldiaminoethylglycine to soft contact lenses increased by the addition of menthol. On the other hand, by adding taurine in addition to menthol, it was confirmed that the adsorption of alkyldiaminoethylglycine to soft contact lenses tended to be suppressed.

[0206] However, when the concentration of alkyldiaminoethylglycine hydrochloride was 0.005 w / v%, such an effect was not observed.

[0207] Test Example 3: Study on amphoteric surfactants

[0208] Since alkyldiaminoethylglycine is an amphoteric surfactant, lauryldimethylaminoacetic acid, which is another amphoteric surfactant, was also studied. Specifically, under the same conditions as in Test Example 1, the adsorption rate of alkyldiaminoethylglycine on soft contact lenses was determined using a preparation of the composition shown in Table 3 using lauryldimethylaminoacetic acid (manufactured by Fujifilm and Koshun Pharmaceutical Co., Ltd.) instead of alkyldiaminoethylglycine hydrochloride. Furthermore, the adsorption inhibition rate (%) was calculated under the same conditions as in Example 2. The results are shown in Table 3. The numerical values ​​in Table 3, except for pH, ADG adsorption rate and adsorption inhibition rate, are expressed as w / v%.

[0209] Table 3

[0210]

[0211] As shown in the results in Table 3, although both are amphoteric surfactants, unlike alkyldiaminoethylglycine, the adsorption amount of lauryldimethylaminoacetic acid to soft contact lenses is small in itself, and the adsorption amount is not significantly increased by the addition of menthol, and the adsorption amount is not reduced by the addition of taurine.

[0212] Therefore, it was revealed that adsorption to soft contact lenses, increase in the amount of adsorption due to menthol, and suppression of adsorption due to the addition of taurine are phenomena unique to alkyldiaminoethylglycine even among amphoteric surfactants.

[0213] Test Example 4: Study of Buffer

[0214] Using the preparations of the composition shown in Table 4, the adsorption rate and adsorption inhibition rate of alkyldiaminoethylglycine on soft contact lenses were determined under the same conditions as in Test Example 2. The results are shown in Table 4. The numerical values ​​in Table 4 are expressed in w / v % except for pH, ADG adsorption rate and adsorption inhibition rate.

[0215]

[0216] As shown in the results in Table 4, even when a boric acid buffer was used as a buffer instead of a phosphate buffer, it was confirmed that the amount of adsorption of alkyldiaminoethylglycine on a soft contact lens, which was increased by the addition of menthol, tended to be reduced by adding taurine in addition to menthol.

[0217] Embodiments 10 to 15

[0218] A pharmaceutical composition for soft contact lens having the composition shown in Table 5 was prepared according to Test Example 1. The numerical values ​​in Table 5, except for pH, represent w / v%.

[0219] Table 5

[0220]

Claims

1. Use of taurine for inhibiting adsorption of alkyldiaminoethylglycine to a soft contact lens in a pharmaceutical composition for soft contact lens containing 0.001 w / v% or more and 0.0045 w / v% or less of alkyldiaminoethylglycine hydrochloride and menthol.

2. A method for inhibiting adsorption of alkyldiaminoethylglycine to a soft contact lens, comprising mixing taurine into a pharmaceutical composition for a soft contact lens containing 0.001 w / v% to 0.0045 w / v% of alkyldiaminoethylglycine hydrochloride and menthol.

3. The use according to claim 1 or the method according to claim 2, wherein the pharmaceutical composition for soft contact lenses contains 0.002 w / v% to 0.004 w / v% of alkyldiaminoethylglycine hydrochloride.

4. The use according to claim 1 or the method according to claim 2, wherein the pharmaceutical composition for soft contact lenses contains 0.0005 w / v% or more and 0.1 w / v% or less of menthol. 5 . The use according to claim 1 or the method according to claim 2 , wherein the pharmaceutical composition for soft contact lenses contains 0.01 w / v % or more and 1 w / v % or less of taurine.

6. The use according to claim 1 or the method according to claim 2, wherein the pharmaceutical composition for soft contact lenses comprises: 0.002 w / v% or more and 0.004 w / v% or less of alkyldiaminoethylglycine hydrochloride, 0.001 w / v% to 0.035 w / v% of menthol, and 0.05 w / v% or more and 0.5 w / v% or less of taurine.

7. The use according to claim 1 or the method according to claim 2, wherein the pharmaceutical composition for soft contact lenses further contains a nonionic surfactant.

8. The use according to claim 1 or the method according to claim 2, wherein the pharmaceutical composition for soft contact lenses further contains glucose.

9. The use according to claim 1 or the method according to claim 2, wherein the pharmaceutical composition for soft contact lenses further contains an inorganic salt.

10. The use according to claim 1 or the method according to claim 2, wherein the pharmaceutical composition for soft contact lenses further contains a thickener.

11. The use according to claim 1 or the method according to claim 2, wherein the pharmaceutical composition for soft contact lenses further comprises a buffer.

12. The use according to claim 1 or the method according to claim 2, wherein the pharmaceutical composition for soft contact lenses comprises: 0.002 w / v% or more and 0.004 w / v% or less of alkyldiaminoethylglycine hydrochloride, 0.001 w / v% to 0.035 w / v% of menthol, 0.05 w / v% or more and 0.5 w / v% or less of taurine, 0.005 w / v% or more and 0.05 w / v% or less of a nonionic surfactant, 0.002 w / v% or more and 0.008 w / v% or less of glucose, 0.1w / v% or more and 2w / v% or less of inorganic salts, 0.05 w / v% or more and 0.5 w / v% or less of a thickener, and 0.1 w / v% or more and 2 w / v% or less of a buffer. 13 . The use according to claim 1 or the method according to claim 2 , wherein the pH of the pharmaceutical composition for soft contact lens is 5.5 or more and 8.0 or less.